This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Small-Cap Winners & Losers

The small-cap sector struggled to keep its head above water along with the rest of the market Wednesday despite good news from names like Beacon Power (BCON).

Beacon, which makes products to support electricity-grid operation, said it will now order the rest of the materials necessary to build its first 10 commercial flywheel units, having successfully completed "all critical performance tests" on its Smart Energy 25 flywheel. Shares of the Wilmington, Mass., company leapt 15.2% to $1.89.

France-based biopharma Flamel Technologies (FLML), meanwhile, licensed its Medusa delivery technology to drugmaking giant Wyeth (WYE) for development of a marketed protein. Medusa is designed to deliver controlled-release formulations of therapeutic proteins and other molecules without reduction in bioactivity.

Flamel shares spiked 86 cents, or 9.4%, to $10; Wyeth recently slipped 1.5% to $45.60.

Elsewhere in the health-care sector, an Oppenheimer analyst said NPS Pharmaceuticals' (NPSP) proposed drug for short bowel syndrome, Gattex, shows strong promise and would play to a largely underserved market. He began coverage of the New Jersey-based with a buy rating, after which shares jumped 14.2% to $4.69.

Business-software firm Catapult Communications (CATT), based in Mountain View, Calif., boosted its prior sales outlook for the fiscal fourth quarter to between $9.5 million and $10.5 million. That's at least $500,000 higher than the only analyst's estimate, as per Thomson Financial. Shares ratcheted up 13.7% to $7.32.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
NPSP $45.97 0.02%
BIOM $0.01 0.00%
FLML $14.43 0.00%
AAPL $117.81 0.00%
FB $105.45 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs